11 recruiting, 3 completed, 3 unknown, 2 not yet recruiting. 20 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Recruiting 11, Completed 3, Unknown 3, Not yet recruiting 2, Active not recruiting 1 |
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02) Second-Line Chemotherapy, Radiation Therapy, Cadonilimab (AK104) - Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer | Phase 3 | Recruiting | Fudan University | 198 | 2026-10-01 | 2026-10-13 |
| Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer Short-Course Radiotherapy, Consolidation treatment (With ICIs), Consolidation treatment (Without ICIs) - Local Advanced Rectal Cancer, Radiotherapy | Phase 3 | Recruiting | Shandong Cancer Hospital and Institute | 180 | 2026-08-15 | 2026-08-18 |
| A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer Short-course radiotherapy, Long-course radiotherapy, Capecitabine - Rectal Cancer, Total Neoadjuvant Therapy | Phase 3 | Recruiting | Tao Zhang | 444 | 2026-05-15 | 2026-05-13 |
| Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection Atezolizumab - Hepato Cellular Carcinoma (HCC), Immunotherapy | Phase 3 | Not yet recruiting | University of Geneva, Switzerland | 30 | 2026-03-25 | 2026-03-10 |
| CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC PD-1 inhibitor, Unlimited radiotherapy, TP regimen - Esophageal Carcinoma, Radiotherapy | Phase 3 | Recruiting | Fudan University | 452 | 2025-02-01 | 2026-04-17 |
| Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer Neoadjuvant therapy, Hypo-RT and concurrent chemotherapy, CFRT and concurrent chemotherapy - Neoadjuvant Therapy, Concurrent Chemoradiotherapy | Phase 3 | Recruiting | Sun Yat-sen University | 497 | 2024-11-30 | 2025-07-24 |
| Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study Anti-PD-1 antibody drug named Serplulimab, Radiotherapy, Chemotherapy - Locally Advanced Rectal Cancer (LARC), Immunotherapy | Phase 3 | Recruiting | West China Hospital | 184 | 2024-11-19 | 2025-06-13 |
| TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC Immunotherapy, chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens, TDLN-sparing RT - Esophageal Carcinoma, Radiotherapy | Phase 3 | Recruiting | Fudan University | 432 | 2024-11-01 | 2026-01-07 |
| Nutrition Impact on Immunotherapy of Cancer Megestrol Acetate and olanzapine, Starch powder 50 mg - Nutrition Disorders, Immunotherapy | Phase 3 | Recruiting | Qingdao Central Hospital | 300 | 2024-06-01 | 2024-07-15 |
| Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases Serplulimab combined with bevacizumab and first-line chemotherapy - Non-small Cell Lung Cancer Stage II, Bevacizumab | Phase 2 / Phase 3 | Completed | Sun Yat-sen University | 40 | 2023-05-14 | 2024-11-13 |
| Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma Camrelizumab, Apatinib Mesylate, Radical surgery - Hepatocellular Carcinoma, Immunotherapy | Phase 3 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 130 | 2023-01-31 | 2024-12-31 |
| Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer xintilimab injection, Control - Neoadjuvant Chemoradiation Therapy, Rectal Cancer | Phase 2 / Phase 3 | Completed | Changhai Hospital | 201 | 2022-10-01 | 2026-01-02 |
| Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy Toripalimab, Tegafur, IMRT - Esophageal Cancer, Radiation Therapy | Phase 2 / Phase 3 | Unknown | Taizhou Hospital | 60 | 2022-07-01 | 2023-04-18 |
| An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC Triprilimab(JS001), Cisplatin, 5-Fluorouracil - Nasopharyngeal Carcinoma, Metastasis | Phase 2 / Phase 3 | Not yet recruiting | Sun Yat-sen University | 622 | 2021-07-01 | 2021-05-18 |
| PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML Visilizumab - Immunotherapy, Refractory Leukemia | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 30 | 2021-05-01 | 2021-12-03 |
| Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma Camrelizumab, Apatinib Mesylate, Radical surgery - Hepatocellular Carcinoma, Immunotherapy | Phase 2 / Phase 3 | Active not recruiting | Shanghai Zhongshan Hospital | 294 | 2021-03-25 | 2025-05-11 |
| Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection Sintilimab, Bevacizumab - HCC, Adjuvant Therapy | Phase 3 | Unknown | Sun Yat-sen University | 246 | 2020-12-01 | 2020-12-23 |
| Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot) - Immunotherapy | Phase 3 | Completed | Johann Wolfgang Goethe University Hospital | 34 | 2004-05-01 | 2007-10-05 |
| Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer Radiotherapy, Platinum based chemotherapy, Paclitaxel based chemotherapy - Esophagus Cancer, Esophagogastric Junction Cancer | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2000 | 2002-01-01 | 2026-01-21 |
| Neoadjuvant Treatment Modalities in Esophageal Cancer Platinum based chemotherapy, Paclitaxel based chemotherapy, Radiotherpay - Esophageal Cancer, Chemotherapy Effect | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2000 | 2002-01-01 | 2026-01-21 |
Esophageal Neoplasms (5) · Carcinoma, Hepatocellular (3) · Neoplasm Metastasis (2) · Neoplasms (2) · Rectal Neoplasms (2) · Asthma (1) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Nasopharyngeal Carcinoma (1) · Nutrition Disorders (1) · Prosthesis Failure (1) · Recurrence (1)
Neoplasms (13) · Neoplasms by Site (12) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Gastrointestinal Diseases (7) · Gastrointestinal Neoplasms (7) · Head and Neck Neoplasms (6) · Esophageal Diseases (5) · Neoplasms by Histologic Type (5) · Carcinoma (4) · Neoplasms, Glandular and Epithelial (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Adenocarcinoma (3) · Liver Diseases (3)
Immunotherapy (3) · Radiotherapy (3) · Bevacizumab (2) · Cisplatin (2) · Platinum Compounds (2) · apatinib (2) · camrelizumab (2) · nimotuzumab (2) · Azacitidine (1) · Capecitabine (1) · Cytarabine (1) · Drug Therapy (1) · Fluorouracil (1) · Gemcitabine (1) · Homoharringtonine (1)
Sun Yat-sen University (4) · Fudan University (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Changhai Hospital (1) · Johann Wolfgang Goethe University Hospital (1) · Qingdao Central Hospital (1) · Shandong Cancer Hospital and Institute (1) · Shanghai Zhongshan Hospital (1) · Taizhou Hospital (1) · Tao Zhang (1) · The First Affiliated Hospital of Soochow University (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University of Geneva, Switzerland (1) · West China Hospital (1)
China (18) · Germany (1) · Switzerland (1)
Han Yue, Ph.D (1) · Hui Liu, Professor (1) · Jian Zhou, Doctor (1) · Jinbo Yue, Doctor (1) · Stefan Zielen, M.D., Ph.D. (1) · Xuehao Wang, professor (1) · Yongxiang Xia (1) · Yun-fei Xia, MD (1) · Zhenyu Lin, MD (1)